FDA Approves FLUOROURACIL — Meitheal Pharmaceuticals Inc.

# FDA Approves Meitheal Pharmaceuticals' Generic Fluorouracil Intravenous Formulation The U.S. FDA has approved Meitheal Pharmaceuticals Inc.'s abbreviated new drug application (ANDA) for generic fluorouracil intravenous injection, potentially expanding treatment access and creating competitive pricing pressure in the oncology market for this widely-used chemotherapy agent. The approval of the generic alternative is expected to provide healthcare systems and patients with more affordable options for this established cancer treatment.